Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 26;12:670040. doi: 10.3389/fimmu.2021.670040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhu, Shi, Li, Zhang, Xu, Chen, Cao, Zhang, Liu, Pan, Liu and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

High TMB and neoantigen load of patients with SWI/SNF mutations. (A) Analysis of tumor mutation burden (TMB) values in five independent Memorial Sloan Kettering Cancer Center (MSKCC) cohorts, including the Zehir, Samstein, Rizvi, Naiyer, and Hellmann cohorts (left), and The Cancer Genome Atlas (TCGA) cohort (right). (B) Analysis of neoantigen load in Hellmann (left) and TCGA (right) cohorts. (C, D) Progression-free survival (PFS) curves of patients with non-small cell lung cancer (NSCLC) in the TMB-high group of the Hellmann, Rizvi, and Naiyer (HRN) (C) and Samstein (D) cohorts based on ARID1A, ARID1B, and ARID2 mutations. SWI/SNF, human switch/sucrose nonfermentable. (E) Overall survival (OS) curves of patients with non-small cell lung cancer (NSCLC) in the Zehir cohort based on the human switch/sucrose nonfermentable (SWI/SNF) mutation status.